Kala Pharmaceuticals Company Insiders
KALA Stock | USD 6.91 0.11 1.62% |
Kala Pharmaceuticals' insiders are aggressively selling. The analysis of insiders' sentiment of trading Kala Pharmaceuticals stock suggests that vertually all insiders are panicking at this time. Kala Pharmaceuticals employs about 43 people. The company is managed by 15 executives with a total tenure of roughly 46 years, averaging almost 3.0 years of service per executive, having 2.87 employees per reported executive.
Mark Iwicki Chairman Chairman of the Board and Presidentident, CEO |
Michele LaRussa President Senior Vice President - Regulatory Affairs and Quality Assurance |
Kala Pharmaceuticals' Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
2024-06-26 | Todd Bazemore | Disposed 4653 @ 4.75 | View | ||
2024-05-31 | Todd Bazemore | Disposed 2093 @ 6.09 | View | ||
2024-01-04 | Mark T Iwicki | Disposed 4539 @ 6.73 | View |
Monitoring Kala Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Kala |
Kala Pharmaceuticals' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Kala Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Kala will maintain a workforce of about 33000000 employees by December 2024.Kala Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.4025) % which means that it has lost $0.4025 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.4811) %, meaning that it created substantial loss on money invested by shareholders. Kala Pharmaceuticals' management efficiency ratios could be used to measure how well Kala Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of November 25, 2024, Return On Tangible Assets is expected to decline to -0.79. In addition to that, Return On Capital Employed is expected to decline to -0.86. At present, Kala Pharmaceuticals' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 98.6 M, whereas Total Assets are forecasted to decline to about 53.2 M.The current year's Common Stock Shares Outstanding is expected to grow to about 2.6 M, whereas Net Loss is forecasted to decline to (42.4 M).
Kala Pharmaceuticals Workforce Comparison
Kala Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 9,814. Kala Pharmaceuticals adds roughly 43.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Kala Pharmaceuticals Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Kala Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Kala Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Kala Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-06-01 | 1.2 | 12 | 10 | 28,400 | 48,135 |
2024-03-01 | 2.0 | 12 | 6 | 225,700 | 11,400 |
2023-06-01 | 0.8727 | 48 | 55 | 1,111,237 | 118,545 |
2023-03-01 | 2.0 | 16 | 8 | 174,956 | 526.00 |
2022-12-01 | 0.2 | 1 | 5 | 1,600 | 1,424 |
2022-06-01 | 1.0 | 11 | 11 | 460,000 | 6,110,123 |
2022-03-01 | 0.8333 | 5 | 6 | 1,557,000 | 22,185 |
2021-12-01 | 1.0 | 7 | 7 | 5,820,777 | 102,297 |
2021-06-01 | 1.1429 | 8 | 7 | 1,812,709 | 26,435 |
2021-03-01 | 7.0 | 14 | 2 | 1,050,499 | 56,500 |
2020-06-01 | 3.5 | 21 | 6 | 403,711 | 113,269 |
2020-03-01 | 12.0 | 12 | 1 | 16,216,411 | 31,000 |
2019-09-01 | 1.0 | 2 | 2 | 4,824 | 4,824 |
2018-03-01 | 11.5 | 23 | 2 | 1,504,298 | 9,769 |
2017-09-01 | 0.6066 | 37 | 61 | 17,906,039 | 84,234,264 |
Kala Pharmaceuticals Notable Stakeholders
A Kala Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Kala Pharmaceuticals often face trade-offs trying to please all of them. Kala Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Kala Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Mark Iwicki | Chairman of the Board and Presidentident, CEO | Profile | |
Michele LaRussa | Senior Vice President - Regulatory Affairs and Quality Assurance | Profile | |
Todd Bazemore | President COO | Profile | |
Vincent Kosewski | Senior Vice President - Manufacturing and Supply Chain Management | Profile | |
Mary CPA | CFO Treasurer | Profile | |
CPA CPA | CFO Treasurer | Profile | |
Jill Steier | Executive Communications | Profile | |
Carl Rennie | Executive Management | Profile | |
MBA JD | Chief Officer | Profile | |
Kim Brazzell | Chief Medical Officer | Profile | |
Justin Hanes | Founder Board | Profile | |
Josiah Craver | Senior Controller | Profile | |
Eric Trachtenberg | General Counsel, Corporate Secretary | Profile | |
Francis MD | Chief Advisor | Profile | |
James Patnoe | Commercial Access | Profile |
About Kala Pharmaceuticals Management Performance
The success or failure of an entity such as Kala Pharmaceuticals often depends on how effective the management is. Kala Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Kala management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Kala management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.75) | (0.79) | |
Return On Capital Employed | (0.82) | (0.86) | |
Return On Assets | (0.75) | (0.79) | |
Return On Equity | (5.62) | (5.34) |
Please note, the presentation of Kala Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Kala Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Kala Pharmaceuticals' management manipulating its earnings.
Kala Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Kala Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Kala Pharmaceuticals within its industry.Kala Pharmaceuticals Manpower Efficiency
Return on Kala Pharmaceuticals Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 981.4K | |
Net Loss Per Executive | 2.8M | |
Working Capital Per Employee | 1M | |
Working Capital Per Executive | 3M |
Complementary Tools for Kala Stock analysis
When running Kala Pharmaceuticals' price analysis, check to measure Kala Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kala Pharmaceuticals is operating at the current time. Most of Kala Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kala Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kala Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kala Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |